5040002026-04-215040002026-04-212026-04-215040002026-04-21in-capmkt:FinancialYear1Member5040002026-04-21in-capmkt:FinancialYear2Member5040002026-04-21in-capmkt:FinancialYear3Member5040002026-04-212026-04-21in-capmkt:FinancialYear1Member5040002026-04-212026-04-21in-capmkt:FinancialYear2Member5040002026-04-212026-04-21in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure

504000

Elpro International Limited

ELPROINTL

NOTLISTED

INE579B01039

New

Acquisition (including agreement to acquire)

false

2026-04-21

15:30:00

2026-04-21

Elpro International Limited

Listed Entity (self)

Cohance Lifesciences Limited

11975800000

2647700000

16965800000

false

true

Pharmaceuticals

Investment Purpose

false

Cash

47900000

Cash Consideration of Rupees Four Crores and Seventy Nine Lakhs Only

47900000

Cohance Lifesciences is a culmination of vision, scientific ambition, and purposeful integration. Their story began with a series of intentional moves, starting with the acquisition of RA Chem Pharma. Over time, a deliberate series of mergers and acquisitions—including ZCL Chemicals, Avra Laboratories, Suven Pharmaceuticals, Sapala Organics, and NJ Bio—brought together differentiated capabilities in Pharma CDMO, APIs, Specialty Chemicals, Formulations and next-gen platforms.

2024-2025

11975800000

2023-2024

10513500000

2022-2023

13403300000

India and United States of America